FDA expands approved use of metastatic breast cancer treatment to include male patients

April 4, 2019 – The U.S. Food and Drug Administration today is extending the indication of palbociclib capsules in combination with specific endocrine therapies for hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer in male patients. “Today we are expanding the indication for palbociclib to include male patients based upon data from postmarketing reports and electronic health records showing … (leggi tutto)